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Early Psychosis
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Early identification of subjects at risk of developing psychosis is the key to early intervention. A prospec-
tive study on the psychopathological progress from prodromal state to full-blown psychosis was initiated
in Taiwan in 2006. However, the clinical entity of our interests is ill-defined; therefore, recruitment of at
risk subjects to participate in studies requires innovation. In November 2006, the study team launched a
special clinic for cognitive and perceptual disturbance. In the first year, 142 subjects, mostly aged 16–30
year olds, made an appointment for this special clinic. More than 20 tentative diagnoses were made.
Seventy-six subjects with a gradient of clinical severity were eligible for enrollment, and 68 gave informed
consent to participate in the research. It seems that setting up a special clinic to provide a service for at risk
subjects, combined with certain campaigns, could facilitate their engagement in a longitudinal prospec-
tive study for early psychosis.
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Early intervention for first episode psychosis can
lead to better prognosis.1 Intervention at the pro-
dromal stage of schizophrenia might delay or even
abort the onset of psychosis.2–4 In this regard,
much effort has been invested worldwide during
the past decade.5,6 Early identification of subjects
at risk of developing psychosis is the key to early
intervention.7 The phenomena that are fre-
quently mentioned as heralding signals of schizo-
phrenia are coined with the acronym “CASIS”,8
including cognitive deficits (subjective decline of
intelligence, poor concentration, inefficient learn-
ing, rigid thinking); affective symptoms (inexpli-
cable anxiety, atypical features of depression,
fearfulness, obsession, hypochondriacal ideations);
social isolation (having few close friends; with-
drawn, distant, aloof, or isolated, frequent absence
without identifiable causes); and school failure
(marked deterioration of academic performance,
or quitting school). As the prodromal symptoms
of schizophrenia are usually nonspecific and the
evolution of the clinical course might be intricate
and protracted, early identification of schizophre-
nia is a challenging task.8,9
A prospective study on Psychopathological Pro-
gress of Early Schizophrenia-like Disorder (ESLD)
(SOPRES), granted by the National Health Re-
search Institute, was initiated in 2006, which
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comprised four related projects: clinical phenom-
enological follow-up study, neurobiological
study, family genetic study, and awareness and
pathways to help seeking study. Four psychopatho-
logical stages are going to be validated by SOPRES:
very early stage (with some vague symptoms as
described by CASIS, yet not fitting into common
psychiatric diagnoses, or inexplicable by adjust-
ment reactions); intermediate risk stage (with some
odd appearance, behavior, speech, thoughts, or
perceptual experiences); very high risk stage (with
attenuated or brief intermittent psychotic symp-
toms); and first episode psychosis (FEP). These
have been validated by a set of baseline and follow-
up assessments, including neurobiological eval-
uations of event related potentials and magnetic
resonance spectroscopy; neurocognitive evalua-
tions of attention, memory, visual-motor function
and intelligence quotient; as well as psychosocial
evaluations. The Institutional Review Board of the
study hospital has approved SOPRES.
The clinical entity of ESLD is ill-defined and
the screening of at risk subjects in the general pop-
ulation is not feasible,10,11 therefore, recruitment
of subjects to participate in the study requires in-
novative approaches. One example is the PACE
(personal assessment and crisis evaluation) clinic
that was established in 1994 by the Melbourne
group as the first clinic specifically designed for
adolescents who suspected with prodromal stage
schizophrenia. Another example is the PRIME (pre-
vention through risk identification, management
and education) clinic that was started in New
Haven in 1997 and extended to North Carolina,
Toronto and Calgary in 1999. Both of these are
two of the most important clinics in prospective
studies of prodromal schizophrenia.6 We tried to
adopt a multifaceted approach to schizophrenia
research in community-based populations, which
involved high school teachers, college and public
counseling services, the high risk family (i.e. the
family with schizophrenic patients), psychiatric
clinics affiliated to the university hospital, and 
to general hospitals in metropolitan Taipei, web-
site information, and mass media. In November
2006, a special clinic for cognitive and perceptual
disturbance of adolescents and young adults was
started to highlight our unique aim for screening
assessment, counseling, and appropriate referrals.
In this report, we describe the demographics,
clinical features, the proportion of subjects eligible
to SOPRES among those who visited our special
clinic, the proportion of these eligible subjects
who participated in the study, types of pharma-
cotherapy given, and compliance with follow-up,
to assess the feasibility of setting up a special clinic
to provide a service for at risk individuals and to
recruit subjects for research.
Methods
This was a naturalistic observation of subjects at-
tending the special clinic for cognitive and percep-
tual disturbance of adolescents and young adults
during November 2006 to October 2007.
Description of the special clinic
The special clinic ran regularly on Wednesday af-
ternoons. It was attended by one general psychi-
atrist (Dr C.C. Liu, 1st and 2nd week of the month)
and two child and adolescent psychiatrists (Dr
Y.N. Chiu, 3rd week; and Dr M.C. Lai, 4th week).
People who were suspected to be at risk of psy-
chosis, (as perceived by themselves, their care-
givers, primary psychiatrists, or counselors), could
make an appointment by calling our research 
assistants or psychiatric outpatient nurse for an
initial screening. To invite more subjects for as-
sessment a low-threshold (presenting with CASIS
or worrying if at risk of psychosis) was applied to
invite more subjects for assessment. If the atten-
dees who presented with CASIS were better classi-
fied as having other psychiatric disorders, such as
organic brain syndrome, pervasive developmental
disorder, social phobia, emotional disturbance, or
even chronic psychosis, they were not eligible for
the SOPRES. Each new attendee received a psy-
chiatric diagnostic interview with the attending
psychiatrist lasting at least 30 minutes. The first-
contact psychiatrist referred the subject for inter-
view by another psychiatrist if he or she had
C.C. Liu, et al
544 J Formos Med Assoc | 2010 • Vol 109 • No 7
Special clinic for early psychosis
J Formos Med Assoc | 2010 • Vol 109 • No 7 545
difficulty with clinical judgment. If the subject were
eligible for the SOPRES, he or she was asked for
their informed consent to participate in our study
after a thorough explanation. All subjects were ad-
vised about any type of pharmacological and/or
psychosocial intervention, based on the empirical
judgment of the attending psychiatrist, regardless
of whether the subject was eligible for the SOPRES.
The special clinic was intended to provide initial
assessment rather than long-term follow-up, there-
fore, subjects generally visited once or twice and
then engaged with regular clinical services if
needed, although some of them opted to be fol-
lowed up at our clinic for their convenience.
Assessment and clinical staging
The clinical impression was generally tentative
rather than definitive and we excluded those who
had a clear psychiatric diagnosis of another dis-
order. The attendees who were eligible for the
SOPRES were evaluated by a set of clinical inter-
views that consisted of modified versions of la-
tent schizophrenia scales, structured interview for
schizotypy, and a scale of prodromal symptoms.
The eligible subjects were categorized into different
levels of clinical severity, with reference to the stage
of risk in prodromal schizophrenia as follows:
(1) Very early stage: subjects met CASIS indicators,
but were unable to fit into any other diag-
nostic category.
(2) Intermediate risk stage: subjects with some
odd appearance, behavior, thinking (concrete,
overabstracting, magic), feelings (inappropri-
ate or incomprehensible expression of emo-
tion), speech (circumstantial, stereotypical),
or perceptual experiences (illusions or over-
sensitive to light or noise), not related to the
severity of brief intermittent or attenuated
psychotic symptoms.
(3) Very high-risk stage: subjects with some brief
intermittent or attenuated psychotic symp-
toms, such as unstable idea of reference, vague
persecutory ideations, or transient hallucina-
tions, which did not yet fit into FEP criteria.
(4) FEP: full-blown psychotic symptoms that de-
veloped over the past year, which met the
Diagnostic and Statistical Manual of Mental
Disorders IV diagnostic criteria for schizophre-
nia, schizophreniform disorder, or schizoaf-
fective disorder.
In terms of the risk of converting to full-blown
psychosis, the predictability of staging was ex-
amined based on the clinical, neurobiological,
neurocognitive, and psychosocial follow-up in-
formation, and reassessed annually.
Statistical analyses
The profile of our attendees was displayed by de-
scriptive statistics and a few comparisons between
differences in certain categorical variables were
made by χ2 test. Three case vignettes are presented
as illustrations to portray the psychopathological
progress from prodrome to FEP.
Results
During the first year since November 2006, 142
individuals (76 male; average age: 20.8 ± 4.1 years;
73 aged < 21 years; Table 1) have made appoint-
ments for our special clinic in 43 sessions; 135
actually attended the clinic, 76 were eligible, and
68 of these (89%) signed their consent (Figure).
Among the 68 participants, 15 (22%) did not
agree to participate in the SOPRES until they had
visited more than once. The tentative clinical im-
pression of the 135 who visited the clinic com-
prised a wide range of psychiatric disorders, and
the main diagnoses were roughly clustered into
20 categories (Table 2). Twenty-four of the 76 el-
igible participants were at the very early stage, 12
at the intermediate risk stage, 21 at the very high-
risk stage, and 19 at FEP; only one, two, three and
two subjects at each stage, respectively, declined
to participate in the SOPRES. Significantly more
subjects in the younger age group were not eligi-
ble (41 of 73 subjects aged < 21 years were ineli-
gible vs. 25 of 69 aged ≥ 21 years; χ2 = 5.67, df = 1,
p = 0.017).
For eligible subjects, antipsychotic agents were
prescribed to all subjects with FEP. Twenty of 21 very
high-risk stage patients also received antipsychotics
C.C. Liu, et al
546 J Formos Med Assoc | 2010 • Vol 109 • No 7
alone or together with antidepressants or anxiolyt-
ics/hypnotics: five were using low-dose sulpiride
(≤ 200 mg/day), while the other 15 received sec-
ond generation antipsychotics. Most of the inter-
mediate-risk and the very early stage subjects
were also empirically treated with antipsychotic
agents (31/36), but the majority of these (22/31)
only received low-dose sulpiride (≤ 200 mg/day)
instead of second generation antipsychotics. More
than half of them also received antidepressants
and/or anxiolytics/hypnotics. Those who agreed
to participate in the SOPRES were more likely to
return to clinical services, as revealed by better
compliance with scheduled visits (40 of the 68
recruited subjects complied with their appoint-
ment vs. 1 of the 8 declined subjects has returned
to the clinic after initial assessment; χ2 = 6.18,
df = 1, p = 0.013).
The three case illustrations revealed a range of
psychopathology at each clinical stage. The wide
variety of clinical symptoms demonstrated that
clinical presentation in the very early and inter-
mediate stages could mimic that of depression,
or could be attributed to adjustment reactions, as
Table 1. Gender and age distribution of all attendees
First episode Very high risk Intermediate risk Very early Non-eligible 
Total
psychosis (n = 19) stage (n = 21) stage (n = 12) stage (n = 24) (n = 66)
Gender
Male 9 8 9 12 38
Female 10 13 3 12 28
Age (yr) 21.4 (4.1) 21.1 (4.2) 21.5 (3.6) 22.2 (3.5) 20.01 (4.2) 20.86 (4.1)
Age 
distribution (n)
≤ 15 1 1 0 0 5 7
16–20 8 10 4 8 36 66
21–25 5 4 6 10 13 38
26–30 5 6 2 5 11 29
> 30 0 0 0 1 1 2
Mass media (n = 53)
Ineligible (n = 59) Eligible (n = 76) Absent (n = 7)
Appointed (n = 142)
Hospital (n = 23) School (n = 10) Others* (n = 56)
First episode
psychosis (n = 17/19)
Very high risk
stage (n = 18/21)
Intermediate risk
stage (n = 10/12)
Very early stage
(n = 23/24)
Recruited (n = 68)
Figure. Summary of numbers of eligible and recruited subjects. *Some individuals were referred by more than one 
channel as presented in the text, some were referred indirectly (somebody knowing our special clinic suggested them to
visit), and not everyone has identified their channel of referral.
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seen in Cases 1 and 3. The clinical course might
not necessarily progress to the next stage but it
could be modified after pharmacological treat-
ment (Cases 1 and 2) and psychosocial adjustment
(Case 3). Usually, patients did not receive clinical
attention unless the severity of the disease was at
the very high-risk stage or FEP, as seen in all three
illustrative cases.
Case illustration 1
A 17-year-old high-school student, who had been
treated for depression since she refused to attend
school 1 year ago, was referred to our special
clinic by her primary psychiatrist for aggravated
irritability, unexplainable fearfulness, ambiva-
lence to her mother, and episodic temper tan-
trums over the past 2 months. She was tearful
during the interview and had difficulty in find-
ing the right words to describe how she felt. Idea
of reference and vague persecutory ideation were
detected but no formed delusion or hallucination
was reported. She was admitted to our psychiatric
ward for emotional instability and intermittent
psychotic-like experiences under the impression
of very high-risk prodromal stage of psychosis.
She soon felt much better under treatment with
5 mg/day olanzapine, although she occasionally
still felt insecure for no reason. However, she be-
came emotionally unstable again soon after dis-
charge, despite good treatment compliance. She
needed her mother’s companionship at night for
fear of something she could not identify. In the
next month, she developed persecutory delu-
sions toward her uncle and became extremely re-
sentful towards him. Then, she believed that the
players in a basketball game during a live televi-
sion broadcast knew what she was thinking, and
asserted that they were conspiring to utilize her
for some illegal profit. A diagnosis of paranoid
schizophrenia was ascertained at a later stage.
Case illustration 2
A 25-year-old man visited our regular psychiatric
service for dysphoric mood, interpersonal over-
sensitivity, and some vague hallucination-like ex-
periences. His primary psychiatrist treated him
with 200 mg/day sulpiride and referred him to
our special clinic for suspicion of very high-risk
prodromal psychosis. However, he responded well
to the medication within a short time. He showed
no evidence of prodromal symptoms but poor
coping with interpersonal interactions at his first
visit to our special clinic. We advised him to try
tapering off his medication gradually over the
next 2 months and invited him to participate 
in our research. One year later, he was noted to
be insomniac, irritable and suspicious. He re-
peatedly accused his girlfriend of testing him
and thought that people on the street knew what
he was thinking and that their eyes seemed to 
be giving him some messages. He did not take
antipsychotic agents until 3 months later when
he developed vivid auditory hallucinations with
voices commenting and conversing, made actions,
and was in turmoil. His psychotic symptoms im-
proved greatly soon after he resumed antipsy-
chotic treatment.
Table 2. Distribution of tentative diagnoses of
attendees (n = 142)
Tentative diagnosis n (%)
Very early stage of prodrome 24 (16.9)
Intermediate risk stage of prodrome 12 (8.5)
Very high risk stage of prodrome 21 (14.8)
FEP 19 (13.4)
Schizophrenia (non-FEP) 12 (8.5)
Bipolar disorder 3 (2.1)
Organic brain syndrome 2 (1.4)
Drug psychosis 1 (0.7)
Neurotic depression 3 (2.1)
Obsessive compulsive disorder 3 (2.1)
Sleep disorder 3 (2.1)
Anxiety disorder 2 (1.4)
Eating disorder 2 (1.4)
Social phobia 2 (1.4)
Psychophysiological disorder 2 (1.4)
Stress reaction 4 (2.8)
Other neurotic disorder 7 (4.9)
Pervasive developmental disorder 3 (2.1)
Emotional disturbance 9 (6.3)
Mental retardation 1 (0.7)
Absent 7 (4.9)
FEP = First episode psychosis.
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Case illustration 3
A 21-year-old college student reported that she
was having problems studying at school. She at-
tributed it to maladjustment because during the
past year she had moved from a rural area to a
city to study. She had strange perceptions of the
outside world, and always tried to work out what
was happening around her because everything felt
unreal, and sometimes she felt something famil-
iar although she had not experienced it before
(déja vu). Sometimes she became sentimental and
moody, which was not necessarily related to any
life event, and she was distracted by these negative
feelings. She saw a psychiatrist and adjustment
disorder was impressed by then. She felt relieved
after suspended her schooling. She revealed that
she had difficulty in distinguishing events in the
real world from those depicted by fictional sto-
ries, and often became over-involved in the emo-
tion aroused by stories that she read in books or
watched on film. She could not concentrate on
study after her recent return to school. This time,
she became emotionally disturbed, and experi-
enced vivid delusions of reference, persecutory
delusions, and auditory hallucinations, and she
had to leave school again.
Discussion
A special clinic for cognitive and perceptual distur-
bance can provide a service to people at risk for
schizophrenia, and screen and invite subjects to
participate in longitudinal follow-up studies. From
our initial fieldwork on case recruitment, we found
that the description of prodromal symptoms of
schizophrenia was nonspecific and the concept
of prodromal psychosis was unfamiliar to most
people. Even mental health professionals were not
ready to identify at risk subjects, especially when
the validity of the four hypothetical clinical stages
was pending verification by prospective studies.
The lessons learned from our first year experiences
are summarized below.
Recruitment of subjects with different levels
of clinical severity necessitates a multifaceted 
approach that is tailored for each targeted sub-
population, as suggested by McGorry et al.12 Our
special clinic offered an excellent window for re-
ferral because the 68 subjects represented more
than two thirds of all SOPRES participants re-
cruited during that period of time. The special clinic
promoted our study, thus 89% of the eligible
subjects agreed to participate in the SOPRES. For
those who were hesitant to participate in the re-
search, the special clinic facilitated recruitment
by engaging with subjects from their initial visit.
Fifteen of the 68 participants (22%) did not give
their consent until they had visited the clinic more
than once. For those who agreed to participate in
our study, they were also more likely to receive
follow-up services; thus, the connection formed
with our research team was helpful in engaging
them for further treatment, if necessary.
The nonspecificity of prodromal symptoms is
still the biggest challenge for clinicians with re-
gard to the wide variety of differential diagnoses.
The younger age group (≤ 20 years old) seemed
to have more difficulties recognizing whether their
own problems were risk factors for psychosis,
which is why we had two child and adolescent
psychiatrists (YNC and MCL) in our team. The di-
versity of the attendees diagnoses also suggests a
generally unmet need for mental health services.
It is worth mentioning that 10% of the subjects
were patients with schizophrenia who had already
been treated by their primary psychiatrists for
more than 1 year for symptoms similar to schiz-
ophrenia. This implies that some psychiatrists have
difficulty in telling their patients about a diagnosis
of schizophrenia; probably out of concern about
stigmatization. The empirical pharmacotherapy
that we delivered to prodromal subjects reflected
the fact that, so far, no consensus can provide
clinical guidelines for this clinical entity.5,13
Our results suggest that service and research
could be mutually supportive. We wish to bring
attention to subjects at risk of developing psy-
chosis through establishment of our special clinic,
as with the PACE and PRIME clinics, and hope that
it continues to be a platform for investigation of
prodromal schizophrenia and FEP in Taiwan.
Special clinic for early psychosis
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